Article

Percutaneous Endovascular Management of Occluded HeRO Dialysis Access Device

Portneuf Medical Center and Idaho State University, Pocatello, Idaho 83201, USA.
Vascular and Endovascular Surgery (Impact Factor: 0.77). 10/2009; 44(1):44-7. DOI: 10.1177/1538574409347394
Source: PubMed

ABSTRACT The Hemodialysis Reliable Outflow (HeRO) device is a novel alternative for dialysis access in patients with no suitable veins in the upper extremities. We placed a HeRO device in a 67-year-old woman with end-stage renal disease and 2 months later, it was being used for hemodialysis. After 1 month of uneventful use, the device thrombosed and it was rescued with a percutaneous endovascular approach. The device remains patent 6 months after the intervention.

0 Followers
 · 
92 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ein funktionierender Gefäßzugang ist eine Grundvoraussetzung für die lebenserhaltende Dialysebehandlung bei Patienten mit chronischem Nierenversagen. Komplikationen dieser Gefäßzugänge gehören zu den wesentlichen Gründen der hohen Morbidität und Letalität von dialysepflichtigen Patienten. Das Outcome des Dialyseshunts und damit auch die Lebensqualität des Patienten sind maßgeblich beeinflusst durch das Timing der Shuntanlage, die Selektion der Gefäßregion, die Wahl des Shuntverfahrens sowie die adäquate Nachsorge. Eine autologe arteriovenöse (a.v.) Fistel wird als primärer Dialysezugang angestrebt. Sie bietet im Vergleich zu alloplastischen Materialien (Shuntprothesen, Dialysekatheter) die besten Offenheits- und die geringsten Komplikationsraten. Shuntprothesen sind u.a. aufgrund ihrer hohen Verschlussraten Dialysezugänge der zweiten Wahl. Insbesondere durch pharmakologische oder neue technische Ansätze haben sich erste Fortschritte bei der Verhinderung der durch die neointimalen Hyperplasie bedingten Anastomosenstenosen von Dialyseshunts ergeben. Neue Thrombektomiekatheter haben die Ergebnisse der interventionellen Wiedereröffnung von verschlossenen Shunts zwar deutlich verbessert, jedoch die chirurgischen Verfahren nicht verdrängt. Die Behandlung von Shuntstenosen ist zunehmend eine Domäne der interventionellen Methoden, wobei sich hier momentan abhängig von der Stenosenlokalisation und -ursache verschiedene Therapieempfehlungen über die alleinige Ballonangioplastie hinaus entwickeln. Shuntinduzierte Steal-Syndrome erfordern ein differenziertes Therapiekonzept, das unterschiedliche Faktoren wie das Flussvolumen des Shuntes und seine Lokalisation sowie den Gefäßstatus und die Komorbidität des Patienten berücksichtigen sollte. A well-functioning vascular access is a prerequisite for life-sustaining dialysis treatment in patients with chronic renal failure. Complications of a vascular access belong to the major causes of the high morbidity and mortality in dialysis-dependent patients. The outcome of the dialysis access and patient’s quality of life is dependent on the timing of access creation, selection of the appropriate vascular region, type of access and the follow-up. Autologous arteriovenous (a.v.) fistulae are considered to be the first choice dialysis access. Compared to an alloplastic access (prosthetic grafts, dialysis catheters) a.v. fistulae offer the highest patency and lowest complication rates. Autologous arteriovenous grafts remain the second choice for dialysis access mainly due to high occlusion rates. Particularly pharmacological and new technical approaches have recently provided further progress in prevention of anastomotic stenoses caused by neo-intimal hyperplasia. Access complications are increasingly being managed by interventional therapy. New thrombectomy devices have improved results of interventional revascularization of occluded a.v. accesses but up to now have not replaced surgical techniques. Stenotic lesions of dialysis accesses are predominantly treated by interventional methods. Apart from the sole use of balloon angioplasty, different recommendations for additional interventions have emerged depending on shunt localization and type of stenosis. Shunt-induced steal syndromes require differentiated therapy which considers factors such as access flow and localization as well as vascular status and patient co-morbidities. SchlüsselwörterShuntchirurgie-Hämodialyse-Arteriovenöse Fistel-Dialysekatheter-Shuntprothese KeywordsVascular access surgery-Hemodialysis-Arteriovenous fistula-Centralvenous catheter-Arteriovenous graft
    Gefässchirurgie 12/2010; 15(8):579-588. DOI:10.1007/s00772-010-0813-y · 0.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Hemodialysis Reliable Outflow (HeRO) graft (Hemosphere Inc, Eden Prairie, Minn) offers a new option to provide upper extremity arteriovenous (AV) dialysis access in patients with central venous occlusive disease. Creative use of this device can allow for salvage of failing or threatened AV fistulas and grafts. We present two patients who underwent a modified implantation of the HeRO device for immediate salvage of a malfunctioning AV access. Ipsilateral central venous occlusions were successfully overcome by anastomosing a HeRO device to the existing AV access and tunneled across the chest to the contralateral internal jugular vein.
    Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 05/2012; 56(4):1127-9. DOI:10.1016/j.jvs.2012.04.013 · 2.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: To determine the outcomes of percutaneous interventions for prolonging the patency of the Hemodialysis Reliable Outflow (HeRO) device. MATERIALS AND METHODS: Between January 2007 and August 2011, 73 percutaneous interventions were performed on 26 HeRO devices in 25 patients. The graft was implanted in the upper arm with the outflow catheter tip in the superior vena cava or right atrium. Procedural reports, angiographic images, and clinical notes were retrospectively reviewed. The primary and secondary patency rates after intervention were calculated using the Kaplan-Meier method. RESULTS: The mean time from HeRO implantation to initial dysfunction or thrombosis was 171 days. In 60 (82%) procedures, the HeRO device was thrombosed. An intragraft stenosis was the most common lesion identified (59%; n = 43) followed by an arterial anastomosis stenosis identified in 18% (n = 13). In 22% (n = 16) of procedures in which the HeRO device was thrombosed, an underlying cause was not identified after thrombectomy. The 3-, 6-, and 12-month primary patency rates after intervention were 47%, 37%, and 26% for first-time interventions. The secondary patency rates were 80%, 70%, and 64%. The only complication was pulmonary embolism resulting in death 2 days after HeRO thrombectomy. CONCLUSIONS: Percutaneous interventions on thrombosed and failing HeRO devices yielded acceptable primary and secondary patency rates after intervention in these patients with few, if any, alternatives for hemodialysis access.
    Journal of vascular and interventional radiology: JVIR 02/2013; 24(4). DOI:10.1016/j.jvir.2012.12.027 · 2.15 Impact Factor